Trial Profile
Randomized Study Of Fludarabine And Cyclophosphamide With Or Without Genasense (Bcl-2 Antisense Oligonucleotide) [oblimersen] In Subjects With Relapsed Or Refractory Chronic Lymphocytic Leukemia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Oblimersen (Primary) ; Cyclophosphamide; Fludarabine
- Indications Chronic lymphocytic leukaemia
- Focus Registrational; Therapeutic Use
- Sponsors Genta
- 08 Sep 2009 Five-year survival results published in Journal of Clinical Oncology.
- 04 Jun 2009 Long-term follow-up data was presented at the 14th Congress of the European Hematology Association.
- 06 Jun 2008 Five-year follow-up data were presented at the 44th American Society of Clinical Oncology (ASCO) annual meeting.